Annovis Bio/ANVS

$8.87

-10.76%
-
1D1W1MYTD1YMAX

About Annovis Bio

Annovis Bio, Inc. is a clinical-stage drug platform company addressing neurodegeneration such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). The Company’s pipeline includes Buntanetap, ANVS405 and ANVS301. Its lead product candidate Buntanetap, is an orally administered drug being developed for chronic indications such as AD and PD. Buntanetap is a synthetically produced small molecule, orally administered, brain penetrant compound. Additionally, Buntanetap was observed to protect nerve cells from dying in the brain of traumatic brain injury mice and to protect nerve cells from dying in the eye of glaucoma rats. ANVS405 is an intravenous drug being developed for acute indications and focused on protecting the brain after traumatic brain injury (TBI) and/or stroke. ANVS405 is the same compound as Buntanetap, given in cases of acute head and brain trauma. ANVS301 is an orally administered drug being developed to increase cognitive capability in later stages of AD and dementia.

Ticker

ANVS

Sector

Healthcare

Trading on

NYSE

Industry

Biotechnology & Drugs

CEO

Maria Maccecchini

Employees

5

Headquarters

Malvern, United States

Annovis Bio Metrics

BasicAdvanced
$102.01M
Market cap
-
P/E ratio
-$4.27
EPS
1.59
Beta
-
Dividend rate

What the Analysts think about Annovis Bio

Analyst Ratings

Majority rating from 5 analysts.
Buy

Price Targets

Average projection from 5 analysts.
348.7% upside
High $72.00
Low $26.00
$8.87
Current price
$39.80
Average price target

Annovis Bio Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$0
-
Net income
$-14.7M
54.74%
Profit margin
0%
-

Annovis Bio Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 49.5%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.38
-$1.19
-$1.07
-$1.63
-
Expected
-$1.05
-$0.33
-$1.14
-$1.09
-$1.20
Surprise
-63.9%
256.29%
-6.28%
49.5%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Annovis Bio stock

Buy or sell Annovis Bio stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing